Defining curative endpoints for transfusion‐dependent β‐thalassemia in the era of gene therapy and gene editing

URN to cite this document:: urn:nbn:de:bvb:355-epub-552369
DOI to cite this document:: 10.5283/epub.55236

Corbacioglu, Selim

; Frangoul, Haydar ; Locatelli, Franco ; Hobbs, William ; Walters, Mark

License: Creative Commons Attribution 4.0
PDF
Early View
(1MB)

Date of publication of this fulltext: 21 Dec 2023 07:21

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Wiley.

Details

Preview: Early View

Export bibliographical data

Abstract

β-thalassemia is a monogenic disease that results in varying degrees of anemia. In the most severe form, known as transfusion-dependent β-thalassemia (TDT), the clinical hallmarks are ineffective erythropoiesis and a requirement of regular, life-long red blood cell transfusions, with the development of secondary clinical complications such as iron overload, end-organ damage, and a risk of early ...